Author: Barb Richard

NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer’s Disease Program / NervGen Renews Business Advisory Relationship with Brian McAlister

Vancouver, Canada. November 10, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has retained  George Perry, PhD, the current and founding Editor-in-Chief of the Journal of Alzheimer’s Disease and Semmes Distinguished University […]

NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update

Vancouver, Canada. October 28, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has appointed Dr. Randall Kaye to the Company’s Board of Directors. Separately, NervGen announced that they were advised by its […]

NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-dilutive Funding Sources for NVG-291

Vancouver, Canada. October 19, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce that it has retained the services of Michael Davis, MD, FACS, FRCS (Hon.), Colonel (Ret.), formerly […]

NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders

Vancouver, Canada. October 1, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, provided an update on the development plans for its lead compound, NVG-291, in three primary indications: multiple sclerosis, spinal cord injury […]

NervGen Pharma Announces Annual General Meeting and Company Update to be Held on September 30, 2020

Vancouver, Canada. September 22, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will host its annual general meeting of shareholders (the “AGM”) on Wednesday, September 30, 2020 at 2:00 […]

NervGen Pharma Announces Departure of Chief Operating Officer / LifeSci Advisors Engaged to Provide Investor Relations Services

Vancouver, Canada. September 10, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Lloyd Mackenzie has resigned from his position as Chief Operating Officer effective October 2, 2020 in order to […]

NervGen Pharma Reports Second Quarter 2020 Results / Phase 1 Clinical Study Remains on Track for Q4 2020

Vancouver, Canada. August 21, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the second quarter ended June 30, 2020. Paul Brennan, NervGen’s President & CEO, stated, “We […]

NervGen Pharma Corp. Completes $6.45 Million Public Offering

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. August 10, 2020 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that today it has closed its previously […]

NervGen Pharma Corp. Announces Filing of Prospectus Supplement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. July 30, 2020 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announces that the Company has filed a […]